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Background
The immunogenicity of an autologous dendritic cell (DC)
anti-HIV therapy, AGS-004, was evaluated in a multi-
center Phase 2 trial. The treatment regiment consisted of
four intradermal doses, administered monthly in combi-
nation with anti-retroviral therapy (ART) followed by a
well-controlled structured treatment interruption (STI).
The immunotherapy consisted of monocyte-derived DC
co-electroporated with CD40L in vitro transcribed (IVT)
RNA along with amplified IVT RNA encoding for 4 HIV-1
antigens (GAG, NEF, REV and VPR).
Methods
Cellular immunity was determined simultaneously by
lymphocyte proliferation (CFSE) and cytokine produc-
tion (ICS)) multi-parameter flow cytometry assays using
peripheral blood mononuclear cells from vaccinated indi-
viduals stimulated in vitro with DC electroporated with
either all 4 or the individual HIV RNA. The two assays
were performed according to applicable GCLP guidelines.
Results
Among 28 subjects recruited until now, there were 8 sub-
jects that had already undergone an initial cycle of this
immunotherapy (CAN-HIV-1 pilot study). All other sub-
jects that were naïve to this immunotherapy successfully
completed the immune monitoring phase of the protocol
and were on a treatment interruption of varying lengths.
We performed an analysis of anti-HIV-specific response
by evaluating the proliferation, IFNg production and the
functionality in CD8+ and CD4+ T cells stimulated with
autologous Gag, Nef, Rev and Vpr. Interestingly, the abso-
lute number of proliferating CD8+ T-cells and those pro-
ducing IFNg in response to GAG-peptides showed an
impressive increase after the first vaccination and follow-
ing ART interruption. Preliminary results of these roll-over
subjects indicate an increase in HIV-specific CD8+ T-lym-
phocyte polyfunctional populations following immuno-
therapy which is accentuated after ART treatment
interruption. These populations have mainly a
CD27+CD8+CD45RA- phenotype.
Conclusion
This immunotherapeutic approach may overcome the
lack of polyvalent specificity of the immune response for
autologous HIV-1 antigens that has been one of the rea-
sons for the failure of prior immunotherapies that use
consensus HIV-1 sequences.
from AIDS Vaccine 2009
Paris, France. 19-22 October 2009
Published: 22 October 2009
Retrovirology 2009, 6(Suppl 3):P412 doi:10.1186/1742-4690-6-S3-P412
<supplement> <title> <p>AIDS Vaccine 2009</p> </title> <editor>Anna Laura Ross</editor> <note>Meeting abstracts - A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1742-4690-6-S3-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf</url> </supplement>
This abstract is available from: http://www.retrovirology.com/content/6/S3/P412
© 2009 Yassine Diab et al; licensee BioMed Central Ltd. 